Lv Ranxu, Wang Yong, Sun Jing, Kang Yuqing, Mou Chunyan, Chen Yujing, Feng Zhaoming, Xue Xing
Jinshan District Central Hospital Affiliated to Shanghai University of Medicine & Health Sciences, Shanghai, China.
Shanghai Jinshan District Hospital of Integrated Traditional and Western Medicine, Shanghai, China.
Medicine (Baltimore). 2024 Dec 20;103(51):e40980. doi: 10.1097/MD.0000000000040980.
Over the past 2 decades, lidocaine's application in oncologic surgery has received significant attention. It has potential antitumor effects and acts as a chemosensitizer. The aim of this study is to analyze the process and frontiers of lidocaine application in oncologic surgery over the past 20 years.
A bibliometric analysis was performed and CiteSpace software was used to conduct metrology, co-occurrence, and cluster analysis. Articles retrieved from the Web of Science database from January 1, 2004 to May 27, 2024. Inclusion criteria comprised peer-reviewed original articles or reviews on lidocaine and cancer, excluding conference abstracts, corrigenda, repeated publications, and unrelated articles.
A total of 956 articles were included in this study. Two hundred seventeen were selected for detailed analysis. The annual publication count showed an overall increasing trend, peaking in 2022. The United States emerged as the leading country in terms of publication frequency and centrality. Major research themes included lidocaine's antiproliferative effects, enhancement of chemotherapy efficacy, and various administration methods.
Based on the above results, we draw a conclusion that the relationship between lidocaine and cancer has garnered increasing attention, with research in this area rapidly developing. Lidocaine exhibits significant antitumor effects and potential as a chemosensitizer, enhancing the efficacy of traditional chemotherapy. These findings underscore the importance of further research to fully elucidate lidocaine's mechanisms and its potential clinical applications in oncology.
在过去20年里，利多卡因在肿瘤外科手术中的应用受到了广泛关注。它具有潜在的抗肿瘤作用，并可作为一种化学增敏剂。本研究的目的是分析过去20年里利多卡因在肿瘤外科手术中的应用过程和前沿进展。
进行文献计量分析，并使用CiteSpace软件进行计量、共现和聚类分析。检索了Web of Science数据库中2004年1月1日至2024年5月27日的文章。纳入标准包括关于利多卡因与癌症的同行评审原创文章或综述，排除会议摘要、勘误、重复发表的文章以及无关文章。
本研究共纳入956篇文章。其中217篇被选作详细分析。年度发表数量总体呈上升趋势，在2022年达到峰值。就发表频率和中心性而言，美国是领先国家。主要研究主题包括利多卡因的抗增殖作用、化疗疗效的增强以及各种给药方法。
基于上述结果，我们得出结论，利多卡因与癌症之间的关系日益受到关注，该领域的研究正在迅速发展。利多卡因具有显著的抗肿瘤作用和作为化学增敏剂的潜力，可提高传统化疗的疗效。这些发现强调了进一步研究以充分阐明利多卡因的作用机制及其在肿瘤学中的潜在临床应用的重要性。
